Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease

Journal of Infectious Diseases

Volumn 186, Issue 6, 2002, Pages 829-833

  Humar, Atul ^a   Kumar, Deepali ^a   Boivin, Guy ^b,c   Caliendo, Angela M ^d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HALF LIFE TIME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; LOGISTIC MODELS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RECURRENCE; TIME FACTORS; VIRAL LOAD;

EID: 0037105633     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342601     Document Type: Article

References (11)

1. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients
2. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients
3. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients
4. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant patients
5. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
6. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
7. Clinical utility of quantitative cytomegalovirus virus load determination for predicting cytomegalovirus disease in liver transplant recipients
8. Clinical and epidemiological predictors of recurrent cytomegalovirus disease
9. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis
10. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients
11. Usefulness of DNA virus load quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients